Deep sequencing reveals occurrence of subclonal ALK mutations in neuroblastoma at diagnosis

Clinical Cancer Research

Volumn 21, Issue 21, 2015, Pages 4913-4921

  Bellini, Angela ^a,b   Bernard, Virginie ^a   Leroy, Quentin ^a   Frio, Thomas Rio ^a   Pierron, Gaelle ^a   Combaret, Valérie ^c   Lapouble, Eve ^a   Clement, Nathalie ^a   Rubie, Herve ^d   Thebaud, Estelle ^e   Chastagner, Pascal ^f   Defachelles, Anne Sophie ^g   Bergeron, Christophe ^c   Buchbinder, Nimrod ^h   Taque, Sophie ⁱ   Auvrignon, Anne ^j   Valteau Couanet, Dominique ^k   Michon, Jean ^a   Janoueix Lerosey, Isabelle ^b   Delattre, Olivier ^a,b   Schleiermacher, Gudrun ^a,b   more..

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c CENTRE LÉON BÉRARD   (France)

^d HÔPITAL DES ENFANTS   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f HÔPITAL D ENFANTS   (France)

^g CENTRE OSCAR LAMBRET   (France)

^h HÔPITAL CHARLES NICOLLE   (France)

ⁱ SERVICE DE RHUMATOLOGIE   (France)

^j ARMAND TROUSSEAU HOSPITAL   (France)

^k INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

ADULT; ALK GENE; ALLELE; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PRIORITY JOURNAL; SANGER SEQUENCING; SEQUENCE ANALYSIS; ADOLESCENT; CANCER STAGING; CLONAL EVOLUTION; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; GENOTYPE; HIGH THROUGHPUT SEQUENCING; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MUTATION; PRESCHOOL CHILD; PROGNOSIS; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; ALLELES; CHILD; CHILD, PRESCHOOL; CLONAL EVOLUTION; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE AMPLIFICATION; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; YOUNG ADULT;

EID: 84947219977     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0423     Document Type: Article

References (35)

1. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
2. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012;72:4875-82.
3. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011;469:356-61.
4. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501:338-45.
5. Crockford A, Jamal-Hanjani M, Hicks J, Swanton C. Implications of intratumour heterogeneity for treatment stratification. J Pathol 2014;232:264-73.
6. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481:306-13.
7. Newburger DE, Kashef-Haghighi D, Weng Z, Salari R, Sweeney RT, Brunner AL, et al. Genome evolution during progression to breast cancer. Genome Res 2013;23:1097-108.
8. Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 2015;518:422-6.
9. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013;152:714-26.
10. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27:1026-33.
11. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012;483:589-93.
12. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013;45:279-84.
13. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet 2013;45:12-7.
14. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, et al. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol 2010;28:3122-30.
15. Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967-70.
16. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-5.
17. Schleiermacher G, Janoueix-Lerosey I, Delattre O. Recent insights into the biology of neuroblastoma. Int J Cancer 2014;135:2249-61.
18. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-4.
19. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010;16:4353-62.
20. Carén H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008;416:153-9.
21. Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 2014;26:682-94.
22. Cazes A, Louis-Brennetot C, Mazot P, Dingli F, Lombard B, Boeva V, et al. Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma. Cancer Res 2013;73:195-204.
23. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-60.
24. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297-303.
25. Ihle MA, Fassunke J, König K, Grünewald I, Schlaak M, Kreuzberg N, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer 2014;14:13.
26. Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, Rio Frio T, et al. Emergence of new ALK mutations at relapse of neuroblastoma. J Clin Oncol 2014;32:2727-34.
27. Combaret V, Iacono I, Bellini A, Bréjon S, Bernard V, Marabelle A, et al. Detection of tumor ALK status in neuroblastoma patients using peripheral blood. Cancer Med 2015;4:540-50.
28. Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 2011;3:108ra114.
29. Barone G, Anderson J, Pearson ADJ, Petrie K, Chesler L. New strategies in neuroblastoma: therapeutic targeting of MYCN and ALK. Clin Cancer Res 2013;19:5814-21.
30. Axelrod R, Axelrod DE, Pienta KJ. Evolution of cooperation among tumor cells. Proc Natl Acad Sci U S A 2006;103:13474-9.
31. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012;30:413-21.
32. Cleary AS, Leonard TL, Gestl SA, Gunther EJ. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 2014;508:113-7.
33. Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, et al. The ALK (F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 2012;22:117-30.
34. Zhu S, Lee J-S, Guo F, Shin J, Perez-Atayde AR, Kutok JL, et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 2012;21:362-73.
35. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372:30-9.